These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20092999)

  • 1. Harm reduction healthcare: from an alternative to the mainstream platform?
    Islam MM; Day CA; Conigrave KM
    Int J Drug Policy; 2010 Mar; 21(2):131-3. PubMed ID: 20092999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving health and social care relationships for harm reduction.
    Allman D; Myers T; Schellenberg J; Strike C; Cockerill R; Cavalieri W
    Int J Drug Policy; 2007 May; 18(3):194-203. PubMed ID: 17689366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moving from a project to programmatic response: scaling up harm reduction in Asia.
    Chatterjee A; Sharma M
    Int J Drug Policy; 2010 Mar; 21(2):134-6. PubMed ID: 20079618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public stigma in health and non-healthcare students: attributions, emotions and willingness to help with adolescent self-harm.
    Law GU; Rostill-Brookes H; Goodman D
    Int J Nurs Stud; 2009 Jan; 46(1):107-18. PubMed ID: 18962601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug use, harm reduction, and health policies in Argentina: obstacles and new perspectives.
    Inchaurraga S
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S366-71. PubMed ID: 14648449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Individual' harms, Community 'harms': reconciling Indigenous values with drug harm minimisation policy.
    van der Sterren AE; Anderson IP; Thorpe LG
    Drug Alcohol Rev; 2006 May; 25(3):219-25. PubMed ID: 16753645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm reduction programmes in the Asia--Pacific Region.
    Reid G; Devaney ML; Baldwin S
    Drug Alcohol Rev; 2008 Jan; 27(1):95-8. PubMed ID: 18034387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational guidelines.
    World Health Organization Regional Office for South-East Asia New Delhi
    Lepr Rev; 2006 Sep; 77(3):IX, X, 1-50. PubMed ID: 17172004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of human parasitic diseases: Context and overview.
    Molyneux DH
    Adv Parasitol; 2006; 61():1-45. PubMed ID: 16735161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Young people and drugs: next generation of harm reduction.
    Merkinaite S; Grund JP; Frimpong A
    Int J Drug Policy; 2010 Mar; 21(2):112-4. PubMed ID: 20036526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much will it cost? Estimation of resource needs and availability for HIV prevention, treatment and care for people who inject drugs in Asia.
    Bergenstrom A; McLeod R; Sharma M; Mesquita F; Dorabjee J; Atun R; Lewis G; Rao JV
    Int J Drug Policy; 2010 Mar; 21(2):107-9. PubMed ID: 20144859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Global Fund's leadership on harm reduction: 2002-2009.
    Atun R; Kazatchkine M
    Int J Drug Policy; 2010 Mar; 21(2):103-6. PubMed ID: 20171865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Harm Reduction Coalition.
    Clear A; Springer E; Lanier C
    Newsline People AIDS Coalit N Y; 1998 Jun; ():27-34. PubMed ID: 11367469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for substance abuse in Australia: a comparison of public and private programs.
    McNeese-Smith DK
    Int J Psychiatr Nurs Res; 2003 Sep; 9(1):1025-38. PubMed ID: 14533233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary care physicians in Israel: self-perception of their role in the healthcare system and policy makers' and patients' perception of them as gatekeepers.
    Tabenkin H; Gross R; Greenberg SB; Steinmetz D; Elhayany A
    Isr Med Assoc J; 2001 Dec; 3(12):893-7. PubMed ID: 11794909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public substance abuse and managed behavioral healthcare. American Managed Behavioral Healthcare Association and National Association of State Alcohol and Drug Abuse Directors, Inc.
    Behav Healthc Tomorrow; 1999 Feb; 8(1):25-30. PubMed ID: 10346117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of barriers and facilitators of HIV treatment among injection drug users.
    Wood E; Kerr T; Tyndall MW; Montaner JS
    AIDS; 2008 Jul; 22(11):1247-56. PubMed ID: 18580603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.